Open access
Open access
Powered by Google Translator Translator

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.

2 Dec, 2022 | 14:40h | UTC

Lecanemab in Early Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)


Heralded Alzheimer’s drug works — but safety concerns loom – Nature

Lecanemab and Alzheimer’s: More Data – Science

Expert reaction to phase 3 trial results of lecanemab for early Alzheimer’s disease – Science Media Centre

Alzheimer’s Drug is Hailed Amid Safety Concerns – Health Policy Watch

Related: Second death linked to potential antibody treatment for Alzheimer’s disease – Science


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.